Pollen Allergy Shots: Per-Allergen Efficacy, Regional Map & Evidence
Pollen allergy shots are SCIT formulated against the specific tree, grass, and weed pollens to which a patient is IgE-sensitized — and pollen carries the strongest RCT evidence base in all of immunotherapy. Grass SCIT achieves ~49% symptom and ~80% medication reduction (Walker 2001 JACI); ragweed SCIT reduces season symptoms and peak flow (Creticos 1996 NEJM); birch SCIT achieves ~40% symptom reduction (Bødtger 2002). Cochrane Calderón 2007 meta-analysis: symptom SMD −0.73 across 51 RCTs.
8 peer-reviewed sources
Pollen allergy shots are SCIT targeting tree, grass, and weed pollens with the strongest RCT evidence in immunotherapy — grass/ragweed have NEJM-level data and FDA-approved SLIT tablets also exist for several pollen allergens.
The essentials
Pollen allergy shots are SCIT formulated against the specific tree, grass, and weed pollens to which a patient's IgE is sensitized — and pollen is the allergen category with the strongest randomized controlled trial evidence in the entire immunotherapy literature.
Curex's at-home IgE testing identifies the specific pollens — tree, grass, ragweed — sensitizing a given patient, with board-certified allergist review to map them to the regional pollen calendar before designing an immunotherapy plan. For eligible maintenance patients, Curex then delivers pollen SCIT as one weekly self-administered shot at home for $129/month — a personalized serum sterile-compounded to USP <797> standards, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand — the same disease-modifying injection traditionally given in a clinic.
Allergen-by-allergen efficacy anchors clinical expectations: short ragweed SCIT (Creticos 1996 NEJM, n=77) showed significant reduction in ragweed-season upper-airway symptoms and improved peak flow during ragweed season. Grass SCIT (Walker 2001 JACI) showed approximately 49% symptom-score reduction versus 15% for placebo and approximately 80% medication-score reduction (P=.007). Birch SCIT (Bødtger 2002 Allergy) achieved approximately 40% symptom and 50% medication reduction in a 1-year RCT. Durham 1999 NEJM demonstrated grass SCIT delivered 3 additional years of clinical remission after stopping a 3–4 year course — the foundational disease-modification finding in the field. The Cochrane seasonal AR meta-analysis (Calderón 2007, 51 RCTs, 2,871 patients) synthesized this into a pooled symptom SMD of −0.73 (95% CI −0.97 to −0.50) and medication SMD of −0.57 (95% CI −0.82 to −0.33).
Pollen has a unique advantage over other allergen categories: FDA-approved SLIT tablets exist for the most common sensitizers. Grastek (timothy grass, ALK, ages 5–65), Oralair (5-grass mix, Stallergenes, ages 5–65), and Ragwitek (short ragweed, Merck, ages 5–65 after 2021 expansion) are the only FDA-approved sublingual immunotherapy products for aeroallergens that are not VIT or house dust mite. This makes pollen the only allergen category with both FDA-approved injectable (SCIT) and FDA-approved oral (SLIT tablet) disease-modifying options.
Regional pollen patterns dictate extract content. Northeast: spring trees (oak, birch, hickory) → late spring/summer grasses (timothy, orchard, Kentucky bluegrass) → late summer/fall short ragweed (Ambrosia artemisiifolia) east of the Rockies. Southwest: mountain cedar (Juniperus ashei) peaks December–February in Texas/Oklahoma; Bermuda grass year-round; ragweed in fall. Midwest: ragweed-dominant fall season. Pacific Northwest: alder and birch heavy in early spring.
Mountain cedar SCIT is an honest caveat: the conventional RCT base for Juniperus ashei is thin. Thompson 2020 (Ann Allergy Asthma Immunol 2020;125:311-318) documented intralymphatic cedar data as proof-of-concept only. Cedar SCIT is practiced clinically in Texas and Oklahoma but is extrapolated from the grass and ragweed evidence base — patients deserve this disclosure.
Climate change is a real clinical variable. Ragweed season has lengthened across the Eastern US in recent decades (Ziska et al., peer-reviewed aerobiology literature). Tree-pollen seasons are starting earlier. Patients whose SCIT was calibrated to an 8-week ragweed season a decade ago are now contending with 10–12 weeks. Disease-modification durability (Durham 1999) is the strongest argument for committing to a full SCIT course before the season lengthens further.
How allergy shots retrain your immune system
Pollen SCIT shifts the immune response away from IgE-mediated Th2 inflammation toward allergen-specific IgG4-dominant tolerance. Within weeks of starting build-up, basophil and mast cell reactivity to the pollen extract declines. Over months, allergen-specific IgG4 blocking antibodies rise 10- to 100-fold, competing with IgE for allergen-binding sites. Regulatory T-cell (Treg) populations expand and produce IL-10 and TGF-β, suppressing Th2 cytokines (IL-4, IL-5, IL-13) that drive eosinophil recruitment and IgE production. This molecular reprogramming is what makes SCIT disease-modifying rather than merely symptomatic.
IgE Testing + Regional Pollen Mapping
Specific IgE testing identifies which tree, grass, and weed pollens are driving the patient's immune response. Results are interpreted against the regional pollen calendar to assemble a clinically relevant extract menu.
Build-Up: Weekly Dose Escalation
26–28 weekly injections of escalating extract concentration (conventional; cluster schedules can compress to 7–13 visits). Each injection followed by a mandatory 30-minute observation period per Cox 2011 PP3.
Maintenance: Immune Consolidation
At effective maintenance dose (approximately 7 µg Phl p 5 for timothy grass; 7–20 µg Amb a 1 for ragweed), injections continue every 2–4 weeks for 3–5 years. IgG4 continues rising; Th2 reactivity continues falling. Durham 1999 NEJM documents this consolidation delivers 3 additional years of remission after stopping.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Pollen has the deepest per-allergen RCT evidence base in SCIT. Key landmark trials provide the quantitative efficacy benchmarks for each major pollen category.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Pollen-allergic patients have more treatment options than any other allergen category — both injectable SCIT and FDA-approved SLIT tablets exist for the most common sensitizers.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (pollen allergy shots) | |||||
SLIT tablets (Grastek/Oralair/Ragwitek) | |||||
SLIT drops (compounded, off-label) | |||||
Antihistamines + intranasal steroids |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex offers pollen SCIT itself at home — at-home subcutaneous immunotherapy as one weekly self-administered shot at $129/month, a personalized serum sterile-compounded to USP <797> standards and overseen by a board-certified allergist, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand — the same disease-modifying course as the 60–80 traditionally in-office pollen-SCIT injections over 3–5 years, without the clinic visits.
See if at-home shots are right for youFrequently asked questions
Do pollen allergy shots work for tree, grass, AND ragweed at the same time?
Yes — a single SCIT vial is typically compounded as a multi-allergen mixture containing extracts for all relevant sensitized pollens simultaneously: spring tree (oak, birch, hickory), late spring/summer grasses (timothy, orchard, Kentucky bluegrass), and late summer/fall short ragweed. The allergen selection is guided by the patient's IgE profile, not a generic formula. Some incompatible allergens — notably those producing enzymes that could degrade adjacent extracts — may be separated into two vials. The regimen, schedule, and visit count are the same for single-allergen and multi-allergen vials.
Is there a pollen allergy shot for cedar fever?
Mountain cedar (Juniperus ashei) SCIT is practiced clinically in Texas and Oklahoma, where cedar fever affects millions annually. However, the conventional RCT base is thin. Thompson 2020 (Ann Allergy Asthma Immunol 2020;125:311-318) documented intralymphatic cedar immunotherapy as proof-of-concept only. Clinical practice extrapolates from grass and ragweed evidence — your allergist should disclose this when discussing cedar SCIT candidacy. FDA-standardized cedar extract does not exist; non-standardized extracts are used, which means lot-to-lot potency can vary.
Are there FDA-approved alternatives to pollen allergy shots?
Yes — for three pollen allergens, FDA-approved SLIT tablets are available: Grastek (timothy grass, ALK, approved 2014, ages 5–65); Oralair (5-grass mix, Stallergenes, ages 5–65); Ragwitek (short ragweed, Merck, approved 2014, expanded to ages 5–65 in 2021). All three are daily sublingual tablets dissolved under the tongue — no injections. All three carry boxed warnings for anaphylaxis, require a supervised first dose in a medical setting, and require co-prescription of epinephrine. For birch and other tree pollens, no FDA-approved SLIT tablet exists in the US (Itulazax has EMA approval in Europe); SCIT or compounded SLIT drops are the options.
How do pollen allergy shots affect oral allergy syndrome (OAS)?
Pollen SCIT — particularly birch SCIT — can improve oral allergy syndrome (OAS) symptoms in some patients, though this is supported by observational data rather than RCTs. OAS in birch-sensitized patients results from IgE cross-reactivity between Bet v 1 (birch pollen protein) and PR-10 food homologs in raw apple (Mal d 1), hazelnut (Cor a 1), cherry (Pru av 1), and peach (Pru p 1). As SCIT reduces overall Bet v 1 sensitization, cross-reactive food reactivity may diminish — but this is a secondary benefit that should not be cited as a primary indication for SCIT. Some patients see no OAS improvement despite successful pollen SCIT.
Does climate change affect whether I need pollen allergy shots?
Climate change is changing the cost-benefit math on pollen immunotherapy. Ragweed season has lengthened across the Eastern US due to later first-frost dates and higher CO2 levels (Ziska et al., peer-reviewed aerobiology literature), and tree-pollen seasons are starting earlier. Patients whose symptoms were seasonal and limited may now face 10–12 week ragweed seasons instead of 8 weeks. As the annual pollen burden increases, disease modification through SCIT — which delivers benefit for 3–12 years post-course per Durham 1999 — becomes more compelling compared to taking antihistamines and intranasal steroids for a lengthening season indefinitely.
What is the minimum number of pollen allergy shots needed to see results?
There is no established "minimum effective dose" in terms of injection count. The Cochrane Calderón 2007 meta-analysis captures data from trials using 3-year standard courses. Durham 1999 NEJM tested a full 3–4 year grass SCIT course and documented 3 additional years of benefit after stopping. The 2-year GRASS trial (Scadding 2017 JAMA) found shorter courses insufficient to establish durable immunological memory. Most patients notice meaningful symptom improvement within the first pollen season after reaching maintenance dose (typically month 6–8 of a conventional build-up schedule), but completing the full 3–5 year course is required for the disease-modifying durability benefit.
What is the systemic reaction rate for pollen allergy shots?
Systemic reactions occur at approximately 0.1% of injection visits across all SCIT types, including pollen SCIT, with approximately 1.9% of SCIT patients experiencing at least one systemic reaction during their course (Epstein TG et al., J Allergy Clin Immunol Pract 2014;2:161-167). The fatality rate is approximately 1 per 23.3 million injection visits, 2008–2012. This is why the 30-minute observation period after every injection is mandatory under Cox 2011 PP3. Local reactions are far more common — occurring in approximately 78–82% of patients at some point — but are generally mild, manageable, and not a reason to stop treatment.
Related Articles
Allergy Shots for Hay Fever — History & Evidence | Curex
Hay fever SCIT: Noon's 1911 Lancet protocol. Cochrane 2007: SMD −0.73 (51 RCTs). Durham 1999: 3-yr remission. At-home shots starting at $129/mo via Curex.
Read moreRagweed Allergy Shots: Evidence & Options | Curex Guide
Ragweed SCIT: strongest US single-allergen RCT (Creticos 1996 NEJM). Ragwitek FDA-approved ages 5–65. Season extended to 10–12 wks. At-home shots: $129/mo.
Read moreAllergy Desensitization Therapy: Program Guide | Curex
Allergy desensitization therapy is a 3-5 year SCIT program: 24-28 weekly build-up visits, then monthly maintenance. Durham 1999 NEJM: durable remission after course ends.
Read moreTypes of Allergy Injections: Full Guide | Curex
Types of allergy injections include SCIT (immunotherapy), biologics like Xolair and Dupixent, depot steroids, and epinephrine. Only SCIT modifies the underlying disease.
Read moreAllergy Shots Pollen — Top-Funnel Guide | Curex
Allergy shots for pollen are SCIT targeting your specific IgE-sensitized pollens. Cochrane 51 RCTs: symptom SMD −0.73. 60–80 injections over 3–5 years. Full beginner guide.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.